Hello
Our lab is dedicated to advancing cell-based and biomaterial-based therapies to address these critical health issues. In particular, we explore the potential of extracellular vesicles (EVs), also known as exosomes, derived from human stem cells, blood serum, and platelets, as innovative treatments for conditions like myocardial infarction and kidney ischaemia. We are passionate about understanding how the origin of these EVs influences their cargo and, consequently, their therapeutic potential. Our investigations revolve around harnessing these tiny biological messengers to stimulate the growth of new blood vessels (angiogenesis), modulate the immune response (immunomodulation), and control cell death (apoptosis) in response to injury. To enhance their effectiveness, we are also exploring the synergy of EVs with biomaterials to extend their therapeutic activity.
About Dr. David J. Lundy
Dr. David J. Lundy received his BSc in Biomedical Sciences and PhD in Cell Biology from the University of Durham, United Kingdom. His Ph.D. thesis was an industrial collaborative partnership using a novel porous 3D scaffold to form an in vitro model of the human skin epidermal barrier for drug testing.
Following completion of his Ph.D., Dr. Lundy spent four years as a Postdoctoral Research Fellow at Academia Sinica, Taiwan, in Prof. Patrick CH Hsieh’s lab. During this time, he conducted research on stem cells, biomaterials and drug delivery for ischaemic diseases, with publications in journals such as Science Translational Medicine, ACS Nano, Nanoscale, Cell Reports and others. Dr. Lundy is also an inventor on four USA and Taiwan patents relating to biomaterial-based drug delivery technologies.
Dr. Lundy joined Taipei Medical University as a faculty member in January 2019 and continues to research cell therapy, cell-biomaterial responses, and cell-free therapies for ischaemic diseases. He is a reviewer for journals such as Nature Communications, Journal of Extracellular Vesicles, Acta Biomaterialia, Journal of Nanobiotechnology, Journal of Controlled Release, and others.
​
Dr. Lundy was honoured with the 2020-2024 Young Scholar Fellowship award from the Taiwan Ministry of Science & Technology (MOST) and has presented his recent work at international conferences such as the World Biomaterials Congress (WBC), International Society for Extracellular Vesicles (ISEV), Biomedical Engineering Society (BMES), American Heart Association Basic Cardiovascular Sciences (AHA BCVS) and others. He is a professional member of the American Heart Association (AHA), American Chemical Society (ACS), International Society of Extracellular Vesicles (ISEV), and a founding member of Taiwan Circulation Research Society (TCRS).